Amanda Yopp Discusses the Challenges With Treating Multiple Myeloma Patients

The monitoring period after CAR T-cell therapy may be safe if shortened due to the lower incidence of ICANS and CRS 2 weeks after treatment in patients with DLBCL.

Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.

Durable complete responses were observed in patients with TP52-mutated mantle cell lymphoma treated with ibrutinib plus venetoclax.

Laura Zitella, MS, RN, ACNP-BC, AOCN, discusses how newly approved bispecific antibodies are expanding third-line treatment options for patients with diffuse large B-cell lymphoma.

Adding brentuximab vedotin to lenalidomide/rituximab results in a stronger overall survival benefit compared with lenalidomide/rituximab alone in relapsed/refractory diffuse large B-cell lymphoma.

Follow-up with cholesterol control and audiological assessments is suggested for cisplatin-treated patients with cancer.